MacDonald, A et al. “PKU dietary handbook to accompany PKU guidelines.”

Orphanet journal of rare diseases vol. 15,1 171. 30 Jun. 2020, doi:10.1186/s13023-020-01391-y

Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A. Opportunities and challenges for antisense oligonucleotide therapies.

J Inherit Metab Dis. 2021 Jan;44(1):72-87. doi: 10.1002/jimd.12251. Epub 2020 Jun 3. PMID: 32391605; PMCID: PMC7891411.

Wortmann, Saskia B et al. “Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.”

Blood vol. 136,9 (2020): 1033-1043. doi:10.1182/blood.2019004465.

Coughlin, Curtis R 2nd et al. “Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency.”

Journal of inherited metabolic disease vol. 44,1 (2021): 178-192. doi:10.1002/jimd.12332

Ferdinandusse, Sacha et al. “An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids.”

Genetics in medicine : official journal of the American College of Medical Genetics vol. 23,4 (2021): 740-750. doi:10.1038/s41436-020-01027-3

Rubio-Gozalbo, M Estela et al. “Galactokinase deficiency: lessons from the GalNet registry.”

Genetics in medicine : official journal of the American College of Medical Genetics vol. 23,1 (2021): 202-210. doi:10.1038/s41436-020-00942-9

Lei, Yu et al. “Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.”

Hepatology (Baltimore, Md.) vol. 72,5 (2020): 1638-1653. doi:10.1002/hep.31198

van Vliet, Kimber et al. “Aspartame and Phe-Containing Degradation Products in Soft Drinks across Europe.”

Nutrients vol. 12,6 1887. 24 Jun. 2020, doi:10.3390/nu12061887

Shen, Joseph J et al. “The role of clinical response to treatment in determining pathogenicity of genomic variants.”

Genetics in medicine : official journal of the American College of Medical Genetics vol. 23,3 (2021): 581-585. doi:10.1038/s41436-020-00996-9

Welsink-Karssies, Mendy M et al. “Classical galactosemia: neuropsychological and psychosocial functioning beyond intellectual abilities.”

Orphanet journal of rare diseases vol. 15,1 42. 7 Feb. 2020, doi:10.1186/s13023-019-1277-0

Crefcoeur, Loek L et al. “Neonatal carnitine concentrations in relation to gestational age and weight.”

Crefcoeur, Loek L et al. “Neonatal carnitine concentrations in relation to gestational age and weight.” JIMD reports vol. 56,1 95-104. 8 Sep. 2020, doi:10.1002/jmd2.12162

Oussoren, Esmee et al. “Hip disease in Mucopolysaccharidoses and Mucolipidoses: A review of mechanisms, interventions and future perspectives.”

Bone vol. 143 (2021): 115729. doi:10.1016/j.bone.2020.115729

Stroek, Kevin et al. “Critical evaluation of the newborn screening for congenital hypothyroidism in the Netherlands.”

European journal of endocrinology vol. 183,3 (2020): 265-273. doi:10.1530/EJE-19-1048

Lubout, Charlotte M A et al. “Bone mineral density is within normal range in most adult phenylketonuria patients.”

Journal of inherited metabolic disease vol. 43,2 (2020): 251-258. doi:10.1002/jimd.12177

Rymen, Daisy et al. “Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation.”

Genetics in medicine : official journal of the American College of Medical Genetics vol. 22,10 (2020): 1589-1597. doi:10.1038/s41436-020-0933-z

Simons, Nynke et al. “Kidney and vascular function in adult patients with hereditary fructose intolerance.”

Molecular genetics and metabolism reports vol. 23 100600. 11 May. 2020, doi:10.1016/j.ymgmr.2020.100600

Welsink-Karssies, Mendy M et al. “Deep phenotyping classical galactosemia: clinical outcomes and biochemical markers.”

Brain communications vol. 2,1 fcaa006. 29 Jan. 2020, doi:10.1093/braincomms/fcaa006

Hollak, Carla E M et al. “Registries for orphan drugs: generating evidence or marketing tools?.”

Orphanet journal of rare diseases vol. 15,1 235. 3 Sep. 2020, doi:10.1186/s13023-020-01519-0

Haskovic, Minela et al. “Nucleotide sugar profiles throughout development in wildtype and galt knockout zebrafish.”

Journal of inherited metabolic disease vol. 43,5 (2020): 994-1001. doi:10.1002/jimd.12265

Wanders, Ronald J A et al. “Mitochondrial Fatty Acid Oxidation Disorders: Laboratory Diagnosis, Pathogenesis, and the Complicated Route to Treatment.”

Journal of lipid and atherosclerosis vol. 9,3 (2020): 313-333. doi:10.12997/jla.2020.9.3.313

van Wegberg, Annemiek M J et al. “Does the 48-hour BH4 loading test miss responsive PKU patients?.”

Molecular genetics and metabolism vol. 129,3 (2020): 186-192. doi:10.1016/j.ymgme.2019.12.011

Welsink-Karssies, Mendy M et al. “The 1-13 C galactose breath test in GALT deficient patients distinguishes NBS detected variant patients but does not predict outcome in classical phenotypes.”

Journal of inherited metabolic disease vol. 43,3 (2020): 507-517. doi:10.1002/jimd.12207

Molema, F et al. “High protein prescription in methylmalonic and propionic acidemia patients and its negative association with long-term outcome.”

Clinical nutrition (Edinburgh, Scotland) vol. 40,5 (2021): 3622-3630. doi:10.1016/j.clnu.2020.12.027

Stroek, Kevin et al. “Evaluation of 11 years of newborn screening for maple syrup urine disease in the Netherlands and a systematic review of the literature: Strategies for optimization.”

JIMD reports vol. 54,1 68-78. 13 May. 2020, doi:10.1002/jmd2.12124

Hong, Xinying et al. “Toward newborn screening of cerebrotendinous xanthomatosis: results of a biomarker research study using 32,000 newborn dried blood spots.”

Genetics in medicine : official journal of the American College of Medical Genetics vol. 22,10 (2020): 1606-1612. doi:10.1038/s41436-020-0846-x

Balfoort, Berith M et al. “A review of treatment modalities in gyrate atrophy of the choroid and retina (GACR).”

Molecular genetics and metabolism, S1096-7192(21)00762-9. 26 Jul. 2021, doi:10.1016/j.ymgme.2021.07.010

Welsink-Karssies, Mendy M et al. “The Galactose Index measured in fibroblasts of GALT deficient patients distinguishes variant patients detected by newborn screening from patients with classical phenotypes.”

Molecular genetics and metabolism vol. 129,3 (2020): 171-176. doi:10.1016/j.ymgme.2020.01.002

van Rijt, Willemijn J et al. “Enantiomer-specific pharmacokinetics of D,L-3-hydroxybutyrate: Implications for the treatment of multiple acyl-CoA dehydrogenase deficiency.”

Journal of inherited metabolic disease vol. 44,4 (2021): 926-938. doi:10.1002/jimd.12365

Panneman, Daan M et al. “Variants in NGLY1 lead to intellectual disability, myoclonus epilepsy, sensorimotor axonal polyneuropathy and mitochondrial dysfunction.”

Clinical genetics vol. 97,4 (2020): 556-566. doi:10.1111/cge.13706

Welsink-Karssies, Mendy M et al. “Gray and white matter are both affected in classical galactosemia: An explorative study on the association between neuroimaging and clinical outcome.”

Molecular genetics and metabolism vol. 131,4 (2020): 370-379. doi:10.1016/j.ymgme.2020.11.001

Coene, Karlien L M et al. “Monitoring phenylalanine concentrations in the follow-up of phenylketonuria patients: An inventory of pre-analytical and analytical variation.”

JIMD reports vol. 58,1 70-79. 22 Nov. 2020, doi:10.1002/jmd2.12186.001

Het United for Metabolic Diseases (UMD) initiatief is een uniek, innovatief en multidisciplinair samenwerkingsverband dat als doel heeft innovatief onderzoek uit te voeren om de diagnostiek, preventie, behandeling en zorg voor patiënten en gezinnen met een erfelijke metabole ziekte sterk te verbeteren.

Met opbrengsten uit de VriendenLoterij PrijzenMarathon heeft Stichting Metakids het samenwerkingsverband (UMD) van zes universitaire ziekenhuizen kunnen faciliteren. Ook is onderzoek binnen het UMD gestart. Deelnemers van de VriendenLoterij spelen sinds de campagne in 2018 geoormerkt mee voor dit goede doel waardoor dankzij hen nog steeds fondsen geworven worden.
Daarnaast zullen Stichting Metakids en het UMD gezamenlijk en afzonderlijk actief werven voor additionele subsidiegelden om het UMD verder te ontwikkelen tot een duurzaam samenwerkingsverband.

© UMD 2019 - 2022